Comparison of adenoviruses as oncolytics and cancer vaccines in an immunocompetent B cell lymphoma model

Eric A. Weaver, Christopher Y. Chen, Shannon M. May, Mary E. Barry, Michael A. Barry

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

We have screened human adenoviruses (Ads) for oncolytic activity against a variety of mouse and hamster cell lines and have found a number that are susceptible to a variety of Ad serotypes. A20 lymphoma is derived from BALB/c mice and is susceptible to infection and killing by a variety of human Ads. A20 is also a suitable cancer vaccine model, because these cells express a unique immunoglobulin variable region that can be targeted by vaccination. To compare Ads as cancer vaccines versus Ads as oncolytics, A20 tumors were initiated in immunocompetent BALB/c mice. Mice immunized with first-generation Ad5 expressing the A20 immunoglobulin ScFv immunogen (Ad-A20) were protected against A20 lymphomas only when the vaccine was delivered before tumor. In contrast, vaccination after tumor initiation failed to increase survival or delay tumor growth. When Ad serotypes from species B, C, D, and E were tested as oncolytics in vitro, A20 cells were most efficiently killed by species D Ads, with intermediate activity by species B Ads. When tested in vivo in immunocompetent BALB/c mice bearing A20 tumors, single intratumoral injection of species D Ad26 and Ad48 were effective at controlling tumor growth. These data demonstrate that in this immunocompetent mouse cancer model, the oncolytic activity of adenoviruses is more potent than their use as a cancer vaccine. These data in immunocompetent mice lend further support to species D Ads as promising oncolytic viruses against B cell cancers.

Original languageEnglish (US)
Pages (from-to)1095-1100
Number of pages6
JournalHuman gene therapy
Volume22
Issue number9
DOIs
StatePublished - Sep 1 2011

Fingerprint

Cancer Vaccines
B-Cell Lymphoma
Adenoviridae
Neoplasms
Human Adenoviruses
Lymphoma
Vaccination
Oncolytic Viruses
Immunoglobulin Variable Region
Growth
Cricetinae
Immunoglobulins
B-Lymphocytes
Vaccines
Cell Line
Injections
Infection

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Comparison of adenoviruses as oncolytics and cancer vaccines in an immunocompetent B cell lymphoma model. / Weaver, Eric A.; Chen, Christopher Y.; May, Shannon M.; Barry, Mary E.; Barry, Michael A.

In: Human gene therapy, Vol. 22, No. 9, 01.09.2011, p. 1095-1100.

Research output: Contribution to journalArticle

Weaver, Eric A. ; Chen, Christopher Y. ; May, Shannon M. ; Barry, Mary E. ; Barry, Michael A. / Comparison of adenoviruses as oncolytics and cancer vaccines in an immunocompetent B cell lymphoma model. In: Human gene therapy. 2011 ; Vol. 22, No. 9. pp. 1095-1100.
@article{af98290ff0184036b56efa984909e8f8,
title = "Comparison of adenoviruses as oncolytics and cancer vaccines in an immunocompetent B cell lymphoma model",
abstract = "We have screened human adenoviruses (Ads) for oncolytic activity against a variety of mouse and hamster cell lines and have found a number that are susceptible to a variety of Ad serotypes. A20 lymphoma is derived from BALB/c mice and is susceptible to infection and killing by a variety of human Ads. A20 is also a suitable cancer vaccine model, because these cells express a unique immunoglobulin variable region that can be targeted by vaccination. To compare Ads as cancer vaccines versus Ads as oncolytics, A20 tumors were initiated in immunocompetent BALB/c mice. Mice immunized with first-generation Ad5 expressing the A20 immunoglobulin ScFv immunogen (Ad-A20) were protected against A20 lymphomas only when the vaccine was delivered before tumor. In contrast, vaccination after tumor initiation failed to increase survival or delay tumor growth. When Ad serotypes from species B, C, D, and E were tested as oncolytics in vitro, A20 cells were most efficiently killed by species D Ads, with intermediate activity by species B Ads. When tested in vivo in immunocompetent BALB/c mice bearing A20 tumors, single intratumoral injection of species D Ad26 and Ad48 were effective at controlling tumor growth. These data demonstrate that in this immunocompetent mouse cancer model, the oncolytic activity of adenoviruses is more potent than their use as a cancer vaccine. These data in immunocompetent mice lend further support to species D Ads as promising oncolytic viruses against B cell cancers.",
author = "Weaver, {Eric A.} and Chen, {Christopher Y.} and May, {Shannon M.} and Barry, {Mary E.} and Barry, {Michael A.}",
year = "2011",
month = "9",
day = "1",
doi = "10.1089/hum.2011.071",
language = "English (US)",
volume = "22",
pages = "1095--1100",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "9",

}

TY - JOUR

T1 - Comparison of adenoviruses as oncolytics and cancer vaccines in an immunocompetent B cell lymphoma model

AU - Weaver, Eric A.

AU - Chen, Christopher Y.

AU - May, Shannon M.

AU - Barry, Mary E.

AU - Barry, Michael A.

PY - 2011/9/1

Y1 - 2011/9/1

N2 - We have screened human adenoviruses (Ads) for oncolytic activity against a variety of mouse and hamster cell lines and have found a number that are susceptible to a variety of Ad serotypes. A20 lymphoma is derived from BALB/c mice and is susceptible to infection and killing by a variety of human Ads. A20 is also a suitable cancer vaccine model, because these cells express a unique immunoglobulin variable region that can be targeted by vaccination. To compare Ads as cancer vaccines versus Ads as oncolytics, A20 tumors were initiated in immunocompetent BALB/c mice. Mice immunized with first-generation Ad5 expressing the A20 immunoglobulin ScFv immunogen (Ad-A20) were protected against A20 lymphomas only when the vaccine was delivered before tumor. In contrast, vaccination after tumor initiation failed to increase survival or delay tumor growth. When Ad serotypes from species B, C, D, and E were tested as oncolytics in vitro, A20 cells were most efficiently killed by species D Ads, with intermediate activity by species B Ads. When tested in vivo in immunocompetent BALB/c mice bearing A20 tumors, single intratumoral injection of species D Ad26 and Ad48 were effective at controlling tumor growth. These data demonstrate that in this immunocompetent mouse cancer model, the oncolytic activity of adenoviruses is more potent than their use as a cancer vaccine. These data in immunocompetent mice lend further support to species D Ads as promising oncolytic viruses against B cell cancers.

AB - We have screened human adenoviruses (Ads) for oncolytic activity against a variety of mouse and hamster cell lines and have found a number that are susceptible to a variety of Ad serotypes. A20 lymphoma is derived from BALB/c mice and is susceptible to infection and killing by a variety of human Ads. A20 is also a suitable cancer vaccine model, because these cells express a unique immunoglobulin variable region that can be targeted by vaccination. To compare Ads as cancer vaccines versus Ads as oncolytics, A20 tumors were initiated in immunocompetent BALB/c mice. Mice immunized with first-generation Ad5 expressing the A20 immunoglobulin ScFv immunogen (Ad-A20) were protected against A20 lymphomas only when the vaccine was delivered before tumor. In contrast, vaccination after tumor initiation failed to increase survival or delay tumor growth. When Ad serotypes from species B, C, D, and E were tested as oncolytics in vitro, A20 cells were most efficiently killed by species D Ads, with intermediate activity by species B Ads. When tested in vivo in immunocompetent BALB/c mice bearing A20 tumors, single intratumoral injection of species D Ad26 and Ad48 were effective at controlling tumor growth. These data demonstrate that in this immunocompetent mouse cancer model, the oncolytic activity of adenoviruses is more potent than their use as a cancer vaccine. These data in immunocompetent mice lend further support to species D Ads as promising oncolytic viruses against B cell cancers.

UR - http://www.scopus.com/inward/record.url?scp=80053049548&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053049548&partnerID=8YFLogxK

U2 - 10.1089/hum.2011.071

DO - 10.1089/hum.2011.071

M3 - Article

C2 - 21770794

AN - SCOPUS:80053049548

VL - 22

SP - 1095

EP - 1100

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 9

ER -